Prospects for a safe COVID-19 vaccine.
Identifieur interne : 000366 ( Main/Exploration ); précédent : 000365; suivant : 000367Prospects for a safe COVID-19 vaccine.
Auteurs : Barton F. Haynes [États-Unis] ; Lawrence Corey [États-Unis] ; Prabhavathi Fernandes [Suisse] ; Peter B. Gilbert [États-Unis] ; Peter J. Hotez [États-Unis] ; Srinivas Rao [États-Unis] ; Michael R. Santos [États-Unis] ; Hanneke Schuitemaker [Pays-Bas] ; Michael Watson [États-Unis] ; Ann Arvin [États-Unis]Source :
- Science translational medicine [ 1946-6242 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Développement de médicament (MeSH), Essais cliniques comme sujet (MeSH), Humains (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (prévention et contrôle), Modèles animaux de maladie humaine (MeSH), Pandémies (MeSH), Pneumopathie virale (immunologie), Vaccination (MeSH), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (immunologie).
- MESH :
- effets indésirables : Vaccins antiviraux.
- immunologie : Infections à coronavirus, Pneumopathie virale, Vaccins antiviraux.
- prévention et contrôle : Infections à coronavirus.
- Animaux, Développement de médicament, Essais cliniques comme sujet, Humains, Modèles animaux de maladie humaine, Pandémies, Vaccination.
English descriptors
- KwdEn :
- Animals (MeSH), COVID-19 (MeSH), COVID-19 Vaccines (MeSH), Clinical Trials as Topic (MeSH), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Disease Models, Animal (MeSH), Drug Development (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (immunology), Vaccination (MeSH), Viral Vaccines (adverse effects), Viral Vaccines (immunology).
- MESH :
- chemical , adverse effects : Viral Vaccines.
- chemical , immunology : Viral Vaccines.
- chemical : COVID-19 Vaccines.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections.
- Animals, COVID-19, Clinical Trials as Topic, Disease Models, Animal, Drug Development, Humans, Pandemics, Vaccination.
Abstract
Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and postlicensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination.
DOI: 10.1126/scitranslmed.abe0948
PubMed: 33077678
Affiliations:
- Pays-Bas, Suisse, États-Unis
- Californie, Caroline du Nord, Hollande-Méridionale, Maryland, Massachusetts, Texas, Washington (État)
- Leyde, Seattle
- Université de Washington
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospects for a safe COVID-19 vaccine.</title><author><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F" last="Haynes">Barton F. Haynes</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@duke.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Corey, Lawrence" sort="Corey, Lawrence" uniqKey="Corey L" first="Lawrence" last="Corey">Lawrence Corey</name><affiliation wicri:level="4"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Fernandes, Prabhavathi" sort="Fernandes, Prabhavathi" uniqKey="Fernandes P" first="Prabhavathi" last="Fernandes">Prabhavathi Fernandes</name><affiliation wicri:level="1"><nlm:affiliation>Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Antibiotic Research and Development Partnership (GARDP), Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Gilbert, Peter B" sort="Gilbert, Peter B" uniqKey="Gilbert P" first="Peter B" last="Gilbert">Peter B. Gilbert</name><affiliation wicri:level="2"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research, Washington, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research, Washington, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name><affiliation wicri:level="2"><nlm:affiliation>Texas Children's Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Children's Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Rao, Srinivas" sort="Rao, Srinivas" uniqKey="Rao S" first="Srinivas" last="Rao">Srinivas Rao</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Research and Development, Sanofi, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanofi Research and Development, Sanofi, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Santos, Michael R" sort="Santos, Michael R" uniqKey="Santos M" first="Michael R" last="Santos">Michael R. Santos</name><affiliation wicri:level="2"><nlm:affiliation>Foundation for the National Institutes of Health, North Bethesda, MD 20852, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Foundation for the National Institutes of Health, North Bethesda, MD 20852</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Schuitemaker, Hanneke" sort="Schuitemaker, Hanneke" uniqKey="Schuitemaker H" first="Hanneke" last="Schuitemaker">Hanneke Schuitemaker</name><affiliation wicri:level="3"><nlm:affiliation>Janssen Vaccines & Prevention B.V., Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Janssen Vaccines & Prevention B.V., Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Watson, Michael" sort="Watson, Michael" uniqKey="Watson M" first="Michael" last="Watson">Michael Watson</name><affiliation wicri:level="2"><nlm:affiliation>Moderna Inc., Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moderna Inc., Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Arvin, Ann" sort="Arvin, Ann" uniqKey="Arvin A" first="Ann" last="Arvin">Ann Arvin</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33077678</idno><idno type="pmid">33077678</idno><idno type="doi">10.1126/scitranslmed.abe0948</idno><idno type="wicri:Area/Main/Corpus">000236</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000236</idno><idno type="wicri:Area/Main/Curation">000236</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000236</idno><idno type="wicri:Area/Main/Exploration">000236</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prospects for a safe COVID-19 vaccine.</title><author><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F" last="Haynes">Barton F. Haynes</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@duke.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Corey, Lawrence" sort="Corey, Lawrence" uniqKey="Corey L" first="Lawrence" last="Corey">Lawrence Corey</name><affiliation wicri:level="4"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Fernandes, Prabhavathi" sort="Fernandes, Prabhavathi" uniqKey="Fernandes P" first="Prabhavathi" last="Fernandes">Prabhavathi Fernandes</name><affiliation wicri:level="1"><nlm:affiliation>Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Antibiotic Research and Development Partnership (GARDP), Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Gilbert, Peter B" sort="Gilbert, Peter B" uniqKey="Gilbert P" first="Peter B" last="Gilbert">Peter B. Gilbert</name><affiliation wicri:level="2"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research, Washington, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research, Washington, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name><affiliation wicri:level="2"><nlm:affiliation>Texas Children's Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Children's Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Rao, Srinivas" sort="Rao, Srinivas" uniqKey="Rao S" first="Srinivas" last="Rao">Srinivas Rao</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Research and Development, Sanofi, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanofi Research and Development, Sanofi, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Santos, Michael R" sort="Santos, Michael R" uniqKey="Santos M" first="Michael R" last="Santos">Michael R. Santos</name><affiliation wicri:level="2"><nlm:affiliation>Foundation for the National Institutes of Health, North Bethesda, MD 20852, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Foundation for the National Institutes of Health, North Bethesda, MD 20852</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Schuitemaker, Hanneke" sort="Schuitemaker, Hanneke" uniqKey="Schuitemaker H" first="Hanneke" last="Schuitemaker">Hanneke Schuitemaker</name><affiliation wicri:level="3"><nlm:affiliation>Janssen Vaccines & Prevention B.V., Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Janssen Vaccines & Prevention B.V., Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Watson, Michael" sort="Watson, Michael" uniqKey="Watson M" first="Michael" last="Watson">Michael Watson</name><affiliation wicri:level="2"><nlm:affiliation>Moderna Inc., Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moderna Inc., Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Arvin, Ann" sort="Arvin, Ann" uniqKey="Arvin A" first="Ann" last="Arvin">Ann Arvin</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Science translational medicine</title><idno type="eISSN">1946-6242</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>COVID-19 (MeSH)</term><term>COVID-19 Vaccines (MeSH)</term><term>Clinical Trials as Topic (MeSH)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Disease Models, Animal (MeSH)</term><term>Drug Development (MeSH)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (immunology)</term><term>Vaccination (MeSH)</term><term>Viral Vaccines (adverse effects)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Développement de médicament (MeSH)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Modèles animaux de maladie humaine (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (immunologie)</term><term>Vaccination (MeSH)</term><term>Vaccins antiviraux (effets indésirables)</term><term>Vaccins antiviraux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>COVID-19 Vaccines</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>COVID-19</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Drug Development</term><term>Humans</term><term>Pandemics</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Développement de médicament</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Pandémies</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and postlicensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33077678</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>568</Issue><PubDate><Year>2020</Year><Month>11</Month><Day>04</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Prospects for a safe COVID-19 vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabe0948</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abe0948</ELocationID><Abstract><AbstractText>Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and postlicensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination.</AbstractText><CopyrightInformation>Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haynes</LastName><ForeName>Barton F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-7643-9023</Identifier><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corey</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2179-2436</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Prabhavathi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1349-8840</Identifier><AffiliationInfo><Affiliation>Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Peter B</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-2662-9427</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research, Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotez</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Texas Children's Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5999-3623</Identifier><AffiliationInfo><Affiliation>Sanofi Research and Development, Sanofi, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Foundation for the National Institutes of Health, North Bethesda, MD 20852, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuitemaker</LastName><ForeName>Hanneke</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8563-2266</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines & Prevention B.V., Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5316-5373</Identifier><AffiliationInfo><Affiliation>Moderna Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arvin</LastName><ForeName>Ann</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5404-1498</Identifier><AffiliationInfo><Affiliation>Departments of Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33077678</ArticleId><ArticleId IdType="pii">scitranslmed.abe0948</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abe0948</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>Caroline du Nord</li><li>Hollande-Méridionale</li><li>Maryland</li><li>Massachusetts</li><li>Texas</li><li>Washington (État)</li></region><settlement><li>Leyde</li><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F" last="Haynes">Barton F. Haynes</name></region><name sortKey="Arvin, Ann" sort="Arvin, Ann" uniqKey="Arvin A" first="Ann" last="Arvin">Ann Arvin</name><name sortKey="Corey, Lawrence" sort="Corey, Lawrence" uniqKey="Corey L" first="Lawrence" last="Corey">Lawrence Corey</name><name sortKey="Gilbert, Peter B" sort="Gilbert, Peter B" uniqKey="Gilbert P" first="Peter B" last="Gilbert">Peter B. Gilbert</name><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name><name sortKey="Rao, Srinivas" sort="Rao, Srinivas" uniqKey="Rao S" first="Srinivas" last="Rao">Srinivas Rao</name><name sortKey="Santos, Michael R" sort="Santos, Michael R" uniqKey="Santos M" first="Michael R" last="Santos">Michael R. Santos</name><name sortKey="Watson, Michael" sort="Watson, Michael" uniqKey="Watson M" first="Michael" last="Watson">Michael Watson</name></country><country name="Suisse"><noRegion><name sortKey="Fernandes, Prabhavathi" sort="Fernandes, Prabhavathi" uniqKey="Fernandes P" first="Prabhavathi" last="Fernandes">Prabhavathi Fernandes</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Schuitemaker, Hanneke" sort="Schuitemaker, Hanneke" uniqKey="Schuitemaker H" first="Hanneke" last="Schuitemaker">Hanneke Schuitemaker</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000366 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000366 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33077678
|texte= Prospects for a safe COVID-19 vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33077678" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |